Q3 2025 Performance - Net sales reached $70.7 million, a decrease of 10.3% year-over-year[11] - Consumables net sales were $49.8 million, a decrease of 2.6% year-over-year, but would have increased modestly excluding the China distributor transition[11] - Delivery systems net sales were $20.8 million, a decrease of 24.6% year-over-year due to macroeconomic challenges[11] - Adjusted EBITDA was $8.9 million, an increase year-over-year due to lower operational spend partially offset by lower adjusted gross profit[11] - Net loss was $(11.0) million, an improvement of $7.3 million year-over-year due to lower operational spend and higher gross margin, partially offset by lower net sales[11] Financial Guidance - The company estimates Q4 2025 net sales to be between $74.5 million and $81.5 million[14] - The company projects Q4 2025 adjusted EBITDA to be between $6.9 million and $8.9 million[14] - The company forecasts FY 2025 net sales to be between $293 million and $300 million[14] - The company anticipates FY 2025 adjusted EBITDA to be between $37 million and $39 million[14] Market Position - Hydrafacial holds the 1 market share, with 41% of aesthetic practices with microdermabrasion offering Hydrafacial[18] - Hydrafacial has a 64% market share in the U S microdermabrasion category[42]

Company Overview - The company champions small and midsize businesses with a mission to simplify business connections[6,9] - The company operates an essential financial operations platform encompassing spend management, accounts payable, and accounts receivable[10,11] - As of September 30, 2025, the company has 498,000 businesses using its solutions and 83 million network members as of June 30, 2025[15,41] - The company's platform facilitates approximately $357 billion in annualized run rate total payment volume[41] Market Opportunity - The U S opportunity includes 34 million SMBs and sole proprietors, a $75 billion SMB software spend, and $36 trillion in B2B payment volume[21] - The global opportunity encompasses 72 million SMBs and sole proprietors, a $344 billion SMB software spend, and $135 trillion in B2B payment volume[21] Financial Performance - The company's trailing 12 months revenue is $15 billion[47] - The company's core revenue year-over-year growth is 14%[47] - The company's non-GAAP gross margin is 84%[15,47] - 86% of core revenue is derived from existing customers[48]

Financial Performance - Solventum's total sales reached $2,096 million, with a reported increase of 0.7% year-over-year and an organic increase of 2.7% year-over-year[12] - MedSurg segment net sales were $1,206 million, reflecting a reported increase of 2.1% and an organic increase of 1.1% year-over-year[13, 17] - Dental Solutions segment net sales were $340 million, with a reported increase of 8.4% and an organic increase of 6.5% year-over-year[12, 24] - Health Information Systems segment net sales were $345 million, showing a reported increase of 5.9% and an organic increase of 5.6% year-over-year[12, 29] - Purification & Filtration segment net sales were $128 million, a reported decrease of 28.7% but an organic increase of 6.4% year-over-year, representing two months of sales before divestiture[12, 34] Profitability and Cash Flow - The company's GAAP operating margin was 80.6%, while the non-GAAP operating margin was 20.6%[13] - GAAP EPS was $7.22, and non-GAAP EPS was $1.50[13] - Cash from operations was $75 million, and free cash flow was negative $22 million[13] Guidance - The company expects organic sales growth of +2.0% to +3.0%, increasing to the high-end of range, or +2.5% to +3.5% excluding ~50bps of SKU-exit impact[39] - Adjusted EPS is expected to be $5.98 to $6.08, versus a prior range of $5.88 - $6.03[39] - Free cash flow is reduced to $150 million to $250 million from $450 million to $550 million due to the Purification & Filtration divestiture impact[39] - Net interest expense is estimated to be ~$360 million, with total non-operating expense around ~$400 million[40] Strategic Actions - The company completed the sale of the Purification & Filtration segment for approximately $4 billion, generating net proceeds of approximately $3.6 billion, with $2.7 billion used for debt reduction[34]

Business Overview Third Quarter 2025 November 2025 The Backbone for Connected Commerce Safe Harbor This presentation has been prepared by VTEX ("we," "us," "our," "VTEX" or the "Company"). This presentation may contain forward-looking statements relating to such matters as continued growth prospects for the Company, industry trends and product and technology initiatives. These statements are based on currently available information and our current assumptions, expectations and projections about future event ...

Earnings Presentation November 6, 2025 NYSE: PAR partech.com Q3 2025 Forward-Looking Statements. This presentation contains forward-looking statements made pursuant to the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934, as amended, Section 27A of the Securities Act of 1933, as amended, and the Private Securities Litigation Reform Act of 1995, and the accuracy of such statements is necessarily subject to risks, uncertainties and assumptions as to future events that may not prove ...

Financial Performance - Ginkgo's Q3 2025 total revenue was $39 million, a decrease of 56% year-over-year compared to $89 million in Q3 2024[34] - Cell Engineering revenue in Q3 2025 was $29 million, a 61% decrease compared to $75 million in Q3 2024, which includes $45 million of non-cash deferred revenue from Motif[23, 34] - Biosecurity revenue in Q3 2025 was $9 million, a 32% decrease compared to $14 million in Q3 2024[34] - Total Adjusted EBITDA for Q3 2025 was $(56) million, compared to $(20) million in Q3 2024[34] - Ginkgo reaffirms its full year 2025 total revenue guidance of $167-187 million[43] - Ginkgo's cash, cash equivalents, and marketable securities remain strong at $462 million as of Q3 2025[17] - Quarterly cash burn continues to improve, with a 73% decrease from the prior quarter[14] Strategic Focus - Ginkgo is expanding its business model into life science tools and services[54, 96] - Ginkgo believes AI models will impact biotechnology in two ways and is well-positioned to provide tools in both[48, 51, 93, 115] - Ginkgo continues to offer research solutions on top of its in-house robotics, winning new deals in Agriculture and with the US Government[49, 52, 94, 116] - Ginkgo is expanding its frontier autonomous lab in Boston as a showcase[50, 53, 95, 117, 118]

Financial Performance - H&R Block announced a 12% increase to its quarterly dividend in August[28] - The company repurchased 7.9 million shares for $400 million, retiring approximately 6% of outstanding shares[29] - H&R Block reaffirms its FY26 outlook with revenue projected between $3.875 billion and $3.895 billion, and adjusted EPS between $4.85 and $5.00[33] - The company anticipates an effective tax rate of approximately 25% for FY26[33] Strategic Initiatives - H&R Block is finalizing tax season plans, incorporating learnings from the previous year[12] - The company focuses on strengthening marketing messaging, personalizing experiences, and optimizing the sales funnel[15] - H&R Block aims to enhance the client experience in retail and DIY channels, reducing friction and increasing conversion from marketing demand[15] - Key products like Second Look, AI Tax Assist, Tax Pro Review, and Spruce are being leveraged to deliver value and differentiation[15] Market Focus - H&R Block is prioritizing growth among more complex, higher lifetime value filers[53] - The company aims to meet customers where they are, both digitally and in person, combining trusted human expertise with innovation[72]

Subscription Revenue Growth - Total subscription revenue has grown significantly from $3.1 million in 2010 to $252.7 million in 2025[3] - The company provides subscription revenue data broken down by cohort from pre-2010 to 2025[6] Subscription Pet Count - Gross new Core Trupanion pets enrolled in Q3 2025 were 57,671[10] - Total subscription pets enrolled at the end of Q3 2025 were 1,082,412[10] - Excluding MGA pets, total subscription pets enrolled at the end of Q3 2025 were 1,026,780[10] Financial Performance & Outlook - The quarterly average revenue per new pet is $74.31 in Q3 2025[12] - The estimated profit per pet per month is $9.05, leading to a lifetime value of $558 per pet[12] - The estimated Internal Rate of Return (IRR) for new pets enrolled in Q3 2025 is 28%[12] - Free cash flow for the three months ended September 30, 2025, was $23.96 million, compared to $13.38 million for the same period in 2024[15] - The company projects Q4 2025 revenue between $371 million and $377 million and full year 2025 revenue between $1.433 billion and $1.439 billion[17] - The company projects Q4 2025 subscription revenue between $258 million and $261 million and full year 2025 subscription revenue between $986 million and $989 million[17]

August 2025 Important Information Regarding Forward-Looking Statements This presentation includes forward-looking statements regarding future events and our future results that are subject to the safe harbor created under the Private Securities Litigation Reform Act of 1995 and other safe harbors under the Securities Act of 1933 and the Securities Exchange Act of 1934. These statements, among other things, relate to the Company's growth drivers and expected levels of our organic growth; the impact of our in ...

Business Growth - Pacira treated more than 3 million patients per year[4,6,8] - The company is experiencing double-digit compounded annual growth rate in product revenue[4,9] - EXPAREL volume growth in 3Q25 reached 9% year-over-year, marking the highest volume growth in over 3 years[9] - Pacira anticipates product revenue to exceed $1.1 billion by 2030[9] Profitability - Pacira achieved a 5-percentage point gross margin improvement over 2024[4,10] - The company's non-GAAP gross margins are projected to be between 80% and 82%[11,42] Pipeline and Partnerships - Pacira is expanding its clinical pipeline with 5 novel programs in development[4,12] - The company is establishing 5 partnerships, including pipeline and commercial agreements[4,14] Financial Performance - Total revenue for 3Q25 was $180 million[42] - Adjusted EBITDA for 3Q25 was $49 million[42] - The company's cash and investments stand at approximately $246 million[42]